Pimavanserin is a medicine for people with Parkinson's disease who see or believe things that aren't real. It is taken by mouth as a capsule or tablet once a day. It works by blocking one of the brain's serotonin signals without affecting dopamine, which people with Parkinson's need.
Every report comes from a Lived member, sent anonymously.
Have you tried Nuplazid (Pimavanserin) for Parkinson's Disease?
Pimavanserin, sold as Nuplazid, is a prescription medicine for hallucinations and delusions caused by Parkinson's disease psychosis. Hallucinations are seeing, hearing or sensing things that are not there; delusions are fixed false beliefs, such as being convinced a partner is unfaithful or that someone is stealing. These symptoms become more common as Parkinson's progresses, and they can be distressing for both the person and their family. It is an atypical antipsychotic, but in 2016 it became the first medicine FDA-approved specifically for this problem. Before starting any antipsychotic, the care team usually checks for other causes, such as an infection, and may adjust Parkinson's medicines that can contribute to psychosis. Pimavanserin is often considered when symptoms persist after that. Other options doctors use include low-dose clozapine, which is effective but needs regular blood tests, and quetiapine (Seroquel), which has less evidence for this use.
Most antipsychotics reduce psychosis by blocking dopamine, a brain chemical that people with Parkinson's already lack. That blockade can make stiffness, slowness and tremor noticeably worse, which is why many antipsychotics are avoided in Parkinson's. Pimavanserin takes a different route. It does not meaningfully act on dopamine receptors. Instead it blocks and dampens a particular serotonin receptor (called 5-HT2A) that is thought to play a role in hallucinations. Exactly how this relieves psychosis is not fully understood. In the main clinical trial, it did not worsen Parkinson's movement symptoms compared with a placebo, so people can usually stay on their usual Parkinson's medicines.
The usual dose is one 34 mg capsule taken once a day, with or without food. There is no gradual build-up; treatment starts at the full dose. For people who have trouble swallowing, which is common in Parkinson's, the capsule can be opened and its entire contents sprinkled on a tablespoon of applesauce, yogurt, pudding or a liquid nutritional supplement. The mixture should be eaten right away, without chewing, and not saved for later. A 10 mg tablet exists for people who also take certain medicines that raise pimavanserin levels in the blood. In that case the prescriber switches to 10 mg once daily. If a dose is missed, take it when remembered unless the next dose is nearly due; do not take two doses together.
In the trials, the side effects seen more often than with placebo were swelling of the ankles, feet or hands, confusion, nausea, constipation and unsteady walking. Sleepiness, falls, agitation and aggression have also been reported since it came on the market. In older adults with Parkinson's, new unsteadiness or sleepiness is worth taking seriously because it raises the risk of falls. Contact the prescriber promptly if confusion becomes worse, hallucinations increase, or walking becomes noticeably harder after starting. Allergic reactions are uncommon. Swelling of the face, lips or tongue, throat tightness or trouble breathing needs emergency care right away, and anyone who has had such a reaction should not take pimavanserin again. Rash or hives should be reported to the prescriber.
Like all antipsychotics, pimavanserin carries an FDA boxed warning: older adults with dementia-related psychosis who take antipsychotics have a higher risk of death, mostly from heart problems or infections such as pneumonia. Pimavanserin is not approved for psychosis in dementia unless the hallucinations and delusions are related to Parkinson's disease. Many people with Parkinson's psychosis also have dementia, so this is a risk worth discussing openly with the prescriber. Pimavanserin can lengthen the QT interval, a measure on an electrocardiogram (ECG) of how long the heart takes to reset between beats. A longer QT interval can, rarely, lead to a dangerous heart rhythm. For that reason it is generally avoided in people who already have a long QT interval, a history of irregular heartbeat, a slow heart rate, or low potassium or magnesium, and alongside other medicines that lengthen QT. These include some heart rhythm drugs (such as amiodarone or sotalol), some antipsychotics, and some antibiotics (such as moxifloxacin). Pimavanserin is broken down by a liver enzyme called CYP3A4. Medicines that strongly block it, such as the antifungal ketoconazole, raise pimavanserin levels, so the dose is lowered to 10 mg. Medicines that speed it up, such as the antibiotic rifampin or the herbal supplement St. John's wort, can make pimavanserin much less effective and should be avoided. Carbidopa/levodopa does not need a dose change. Tell the prescriber and pharmacist about every new prescription, over-the-counter medicine or supplement. There are no data on pimavanserin in pregnancy or breastfeeding. Kidney disease does not change the dose, but it should be used with caution in severe kidney disease.
Pimavanserin works gradually. In the trial that led to its approval, improvement built steadily over six weeks, so a fair assessment usually takes at least that long. On a symptom scale where participants started at about 15 points, scores dropped by about 6 points on pimavanserin and about 3 points on placebo. That means many people notice hallucinations and delusions becoming less frequent or less upsetting rather than disappearing, and some people do not benefit. The medicine stays in the body for a long time, so changes in either direction unfold over days to weeks. Follow-up visits usually review symptom changes, side effects, falls and any new medicines that could interact. Some clinicians check an ECG, especially for people with heart conditions. Family members or caregivers are often the best observers of change and can help by keeping notes. If pimavanserin is not helping after an adequate trial, the care team may reconsider Parkinson's medicines or try a different approach.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Nuplazid (Pimavanserin), what you've noticed, or ask the community a question.